WW International, Inc. (WW) Earnings
WW International, Inc. is expected to report next earnings on November 5, 2026 (in NaN days), with a consensus EPS estimate of $0.52. WW has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -32.4% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 5, 2026 | $0.48 | $1.41 | +193.8% | $162M | +2.0% |
| May 7, 2026 | $-2.16 | $-5.20 | -140.7% | $168M | +6.1% |
| Mar 16, 2026 | $-0.85 | $-0.58 | +31.5% | $176M | +13.6% |
| Nov 6, 2025 | $-0.14 | $-0.44 | -214.3% | $171M | +14.1% |
| Feb 27, 2025 | $0.01 | $0.32 | +3100.0% | $184M | +6.5% |
| Aug 1, 2024 | $-0.00 | $-0.13 | -4162.3% | $202M | -3.0% |
| May 2, 2024 | $-0.43 | $-0.06 | +86.0% | $207M | +3.0% |
| Feb 28, 2024 | $-0.01 | $-0.06 | -852.4% | $206M | +0.4% |
| Nov 2, 2023 | $0.06 | $0.06 | +0.0% | $215M | -2.7% |
| Aug 3, 2023 | $0.08 | $-0.04 | -150.0% | $227M | -1.1% |
| May 4, 2023 | $-0.37 | $-0.14 | +62.2% | $242M | +2.3% |
| Mar 6, 2023 | $-0.00 | $0.06 | +2778.6% | $224M | -0.6% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 5, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Debt Reduction and Liquidity • The company completed a debt prepayment that reduced term loan principal by $41.4 million, generating a $4.6 million gain on the transaction • Annual interest expense is lowered by approximately $4 million following the prepayment • The outstanding term loan balance now stands at $423.6 million, a reduction of more than 70% from the $1.6 billion balance carried before the company's financial reorganization • The company retains sufficient liquidity to invest in strategic priorities while continuing proactive paydown of remaining debt - Business Progress and Mix Shift • A more disciplined operating model has demonstrated clear earnings power in the second quarter • The company is making solid progress toward its targeted higher-value business mix shift • Core Plus (behavioral segment) has delivered three consecutive quarters of sequential subscriber growth • Clinical subscription revenue continues to grow as a share of total company revenue • The business now has a stronger financial foundation with a meaningfully reduced debt load • Positive operating cash flow is expected to support ongoing strategic investment in the company's transformation - Seasonal Marketing Cadence • Q3 is typically the company's lowest quarter for annual marketing spend • Marketing spending will ramp up in Q4 ahead of the annual peak season, consistent with the company's historical seasonal cadence
Guidance
- The company reaffirms its full-year 2026 guidance, with total revenue targeted between $620 million and $635 million, and adjusted EBITDA targeted between $105 million and $115 million - Clinical subscription revenue is expected to account for 25% to 30% of 2026 total revenue, up from 15.9% in full-year 2025 - 2026 adjusted gross margin is expected to see a modest decline versus 2025, but will remain above 72% - 2026 marketing expense as a percentage of revenue is expected to increase modestly compared to 2025, with second half marketing spend lower than first half spend - Product development spending is expected to remain near the Q2 2026 quarterly run rate for the remainder of the year - The company expects to generate positive full-year 2026 operating cash flow - Full-year 2026 interest costs are projected between $45 million and $50 million, reflecting lower quarterly interest following the Q2 2026 debt prepayment - Quarterly capitalized software and development spending is expected to stay in line with the Q2 2026 run rate - 2026 cash taxes are projected between $5 million and $10 million - Within the behavioral segment, continued year-over-year growth in Core Plus subscribers is expected, alongside continued moderation in the year-over-year rate of end-of-period behavioral subscriber decline
Segment performance
No detailed segment-level financial performance (revenue, absolute performance or revenue contribution percentage for individual product segments) was provided in the released earning call transcript. The only segment-related data noted is that clinical subscription revenue made up 15.9% of total revenue for full-year 2025, and is targeted to reach 25% to 30% of total 2026 revenue. The call also noted that the Core Plus behavioral health product has achieved three consecutive quarters of sequential subscriber growth, with moderation in the year-over-year rate of total behavioral subscriber decline, but no absolute financial figures for any segment were disclosed.
Risks & headwinds
No explicit discussion of business risks or operational failures was included in the provided earning call transcript.